Maxwell, Patrick H. http://orcid.org/0000-0002-0338-2679
Article History
First Online: 11 September 2019
Competing interests
: P.H.M. is a scientific founder and holds equity in ReOx Ltd. He has received a speaker honorarium from Fibrogen. He is head of the School of Clinical Medicine at the University of Cambridge, which has strategic partnerships with AstraZeneca and GlaxoSmithKline, both of which are developing PHD inhibitors for the treatment of renal anaemia.